# A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients

> **NCT01376804** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 57 (actual)

## Conditions studied

- Kidney Transplantation, Cytomegalovirus Infections

## Interventions

- **DRUG:** valganciclovir [Valcyte]

## Key facts

- **NCT ID:** NCT01376804
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-31
- **Primary completion:** 2013-05-31
- **Final completion:** 2013-05-31
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2017-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01376804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01376804, "A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01376804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*